Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject

NCT02303509 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: UCB5857 Part 1
DRUG: UCB5857 Part 2
OTHER: Placebo

Sponsor

UCB Pharma

Collaborators

[object Object]